Bank of New York Mellon
KRON

Bank of New York Mellon’s Kronos Bio KRON Stock Holding History

Bank of New York Mellon’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,618
Closed -$20.8K – 4244
2023
Q4 		$20.8K Hold
16,618
– – ﹤0.01% 4234
2023
Q3 		$21.6K Hold
16,618
– – ﹤0.01% 4249
2023
Q2 		$28.6K Sell
16,618
-115,120
-87% -$183K ﹤0.01% 4246
2023
Q1 		$192K Sell
131,738
-1,739
-1% -$3.33K ﹤0.01% 3936
2022
Q4 		$216K Sell
133,477
-60
-0% -$138 ﹤0.01% 3937
2022
Q3 		$447K Buy
133,537
+11,294
+9% +$51K ﹤0.01% 3621
2022
Q2 		$445K Sell
122,243
-11,150
-8% -$50.5K ﹤0.01% 3666
2022
Q1 		$965K Sell
133,393
-4,741
-3% -$40.4K ﹤0.01% 3340
2021
Q4 		$1.88M Buy
138,134
+2,600
+2% +$40.7K ﹤0.01% 3032
2021
Q3 		$2.84M Buy
135,534
+22,179
+20% +$476K ﹤0.01% 2793
2021
Q2 		$2.71M Buy
113,355
+74,750
+194% +$1.89M ﹤0.01% 2809
2021
Q1 		$1.13M Buy
38,605
+1,238
+3% +$36.3K ﹤0.01% 3258
2020
Q4 		$1.12M Buy
+37,367
New +$1.17M ﹤0.01% 3198

Other funds holding KRON

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bank of New York Mellon's KRON Position: Q1 2024 in Review

Bank of New York Mellon sold out of Kronos Bio (KRON) in Q1 2024, closing a stake of 16,618 shares — an estimated $20.8K sold.

Bank of New York Mellon first reported a position in KRON in Q4 2020 and held it in 13 quarters. The position peaked at $2.84M in Q3 2021. 58 funds tracked by Wall St. Rank hold KRON as of Q1 2024.

  • Bank of New York Mellon reported no remaining Kronos Bio position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 16,618 Kronos Bio shares in Q1 2024, an estimated $20.8K.
  • Bank of New York Mellon first reported a position in Kronos Bio in Q4 2020 and held it in 13 quarters.
  • Bank of New York Mellon's Kronos Bio position peaked at $2.84M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.